Financial Contrast: LadRx (OTCMKTS:CYTR) and SQZ Biotechnologies (NYSE:SQZ)

Valuation & Earnings

This table compares SQZ Biotechnologies and LadRx”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SQZ Biotechnologies	$18.16 million	0.04	-$79.46 million	($2.61)	-0.01
LadRx	N/A	N/A	-$6.70 million	($0.15)	N/A

LadRx has lower revenue, but higher earnings than SQZ Biotechnologies. SQZ Biotechnologies is trading at a lower price-to-earnings ratio than LadRx, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

38.5% of SQZ Biotechnologies shares are held by institutional investors. Comparatively, 0.1% of LadRx shares are held by institutional investors. 16.0% of SQZ Biotechnologies shares are held by company insiders. Comparatively, 12.8% of LadRx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares SQZ Biotechnologies and LadRx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
SQZ Biotechnologies	-369.96%	-119.83%	-59.90%
LadRx	N/A	-67.61%	-45.39%

Risk and Volatility

SQZ Biotechnologies has a beta of 2.34, meaning that its stock price is 134% more volatile than the S&P 500. Comparatively, LadRx has a beta of 1.96, meaning that its stock price is 96% more volatile than the S&P 500.

About SQZ Biotechnologies

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.

About LadRx

LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. The company's advanced drug conjugate, aldoxorubicin that is in late-stage clinical trials is a version of anti-cancer drug doxorubicin. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. LadRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.